We have made amazing progress in the treatment of COVID-19. Two therapies – steroids and remdesivir – have already been shown to help. Those who benefit from these treatments owe thanks to patients who volunteered to participate in controlled clinical trials, and the physicians and pharmaceutical companies that lead them.
The coronavirus has mutated to become more infectious. Does that mean it will become more or less lethal? And what implication does it have for a vaccine and herd immunity?
Vaccines for COVID-19 get most of the headlines. But it is possible, if not likely, that a drug or combination of drugs may be quicker to develop, and possibly will be more effective in controlling the virus. Here's an opinion piece making the case that recently ran in the Baltimore Sun, co-authored by ACSH's Dr. Josh Bloom and ACSH advisor Dr. Katherine Seley-Radtke.
Do people acquire long-term immunity to coronavirus? Will there be a second wave? Will there be more lockdowns? Some recent news helps shed light on these questions.
Most drug and vaccine candidates fail. However, the success rate varies wildly depending on the therapeutic area. The probability that at least one coronavirus vaccine will win FDA approval is quite high, though that does not mean it will work well.
Dr. Michael Osterholm, ACSH advisor and infectious disease epidemiologist, has co-authored a report on the coronavirus, drawing upon lessons learned from previous influenza pandemics. He and his co-authors predict one of three scenarios for how the COVID-19 pandemic will play out.
In order for restaurants in Washington State to reopen for dining in, they will be required to keep a log of customer names and contact information in case contact tracing is necessary. This is smart, not only to fight the coronavirus but foodborne infectious disease outbreaks as well.
If the spread of COVID-19 is unstoppable, infectious disease epidemiologist Dr. Johan Giesecke says that we must shift our public health strategy away from a futile attempt to prevent its spread and toward providing optimal care for the sickest patients.
Media headlines are almost exclusively about the coronavirus death toll and the debate over whether it's too early to begin lifting lockdown restrictions. However, there are several other observations about COVID-19 that are important, but are getting very little attention.
How would we respond differently if another outbreak happened?
The death toll from the coronavirus will place COVID-19 in the top 10 causes of death in the United States in 2020, possibly as high as #3. Yet, it likely will remain far behind the deaths caused by heart disease and cancer.
After months of speculation, the results of the first placebo-controlled trial of remdesivir are out. The drug does help people with COVID-19 disease, but it's nothing to get excited about. Here's why.